Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: A single-center, single-arm, phase 2 trial

The new combination therapy for newly diagnosed Ph+ ALL, using olverembatinib, venetoclax, and reduced-intensity chemotherapy, demonstrated significant effectiveness and safety. It achieved a 62.0% complete molecular response at 3 months, with estimated 1-year overall survival of 93.1% and event-free survival of 89.1%. Notably, no deaths occurred during the induction phase, making it a viable alternative treatment.